VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug Discovery [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
Cuozzo is an experienced scientific leader with a strong track record of building novel discovery platforms and leading successful drug discovery programs. He brings over 20 years of drug discovery experience in both pharma and machine learning enabled biotech companies to VantAI and its mission. Cuozzo joins VantAI from Relay Therapeutics, a clinical-stage precision medicine company, where he served as VP, Discovery Technologies and led teams who leveraged machine learning and high-throughput selection technologies to discover novel small molecule drugs for challenging targets. Prior to Relay, Cuozzo was Head of Drug Discovery at ZebiAI, a company that applied massive DNA-encoded library datasets to power machine learning for drug discovery. ZebiAI spun out of X-Chem, where as VP of Therapeutic Discovery, Cuozzo initiated and led small molecule inhibitor and degrader programs in multiple therapeutic areas, with experience driving innovative targets from target selection stage throu
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Relay Therapeutics to Host New Program and Platform Event on June 6, 2024 [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics to Host New Program and Platform Event on June 6, 2024GlobeNewswire
- Relay Therapeutics, Inc. (NASDAQ: RLAY) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $15.00 price target on the stock.MarketBeat
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $24.00 price target on the stock.MarketBeat
RLAY
Earnings
- 5/2/24 - Beat
RLAY
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/29/24 - Form 4
- RLAY's page on the SEC website